Innogenetics launches Easdaq flotation at $11 a share
This article was originally published in Clinica
Executive Summary
Innogenetics, the Belgian manufacturer and developer of diagnostic and woundcare products, has launched its initial public offering last week, writes Brigitte Ascher. The prospectus assumes a price of $11 a share which would value the company at more than $220 million. With trading set to start on or before November 26th, Innogenetics will become one of the first companies quoted on the Easdaq, the new Brussels-based stock exchange modelled on the US Nasdaq. Shares will be quoted in US dollars.